Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.

[1]  M. Rosolowsky,et al.  Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis. , 1990, The Journal of clinical investigation.

[2]  S. Goldberg,et al.  Does antiplatelet therapy enhance myocardial salvage after coronary reperfusion? , 1990, Journal of the American College of Cardiology.

[3]  G. Gross,et al.  Prostaglandin redirection by thromboxane synthetase inhibition. Attenuation of myocardial stunning in canine heart. , 1990, Circulation.

[4]  L. Becker,et al.  Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. , 1989, Circulation.

[5]  J. Eidt,et al.  Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications , 1989, Circulation.

[6]  P. Janssen,et al.  R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo , 1989, Thrombosis and Haemostasis.

[7]  P. Janssen,et al.  R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - I. Biochemical Profile In Vitro , 1989, Thrombosis and Haemostasis.

[8]  G. Grover,et al.  Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve. , 1989, The Journal of pharmacology and experimental therapeutics.

[9]  G. FitzGerald,et al.  Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. , 1988, Journal of Clinical Investigation.

[10]  D. Caruso,et al.  Nonsteroidal Antiinflammatory Drugs Aggravate Acute Myocardial Ischemia in the Perfused Rabbit Heart: A Role for Prostacyclin , 1988, Journal of cardiovascular pharmacology.

[11]  K. Mullane,et al.  Thromboxane Synthetase Inhibitors Reduce Infarct Size by a Platelet‐Dependent, Aspirin‐Sensitive Mechanism , 1988, Circulation research.

[12]  M. Chiariello,et al.  Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion. , 1988, American heart journal.

[13]  P. J. Simpson,et al.  Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation. , 1988, The Journal of pharmacology and experimental therapeutics.

[14]  G. Grover,et al.  Effect of the Thromboxane Receptor Antagonist SQ 29,548 on Myocardial Infarct Size in Dogs , 1988, Journal of cardiovascular pharmacology.

[15]  P. J. Simpson,et al.  Iloprost Inhibits Neutrophil Function In Vitro and In Vivo and Limits Experimental Infarct Size in Canine Heart , 1987, Circulation research.

[16]  M. Brezinski,et al.  Cardioprotective Actions of Specific Thromboxane Receptor Antagonist in Acute Myocardial Ischemia , 1987, Journal of cardiovascular pharmacology.

[17]  G. Fitzgerald,et al.  Thromboxane A2 biosynthesis in human disease. , 1987, Federation proceedings.

[18]  T. Carew,et al.  The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. , 1987, Circulation.

[19]  M. Ogletree,et al.  Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. , 1985, The Journal of pharmacology and experimental therapeutics.

[20]  E. Liu,et al.  Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro. , 1985, Prostaglandins.

[21]  S. Coker.  Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. , 1984, Journal of molecular and cellular cardiology.

[22]  K. Chien,et al.  Accumulation of Unesterified Arachidonic Acid in Ischemic Canine Myocardium: Relationship to a Phosphatidylcholine Deacylation‐Reacylation Cycle and the Depletion of Membrane Phospholipids , 1984, Circulation research.

[23]  C. Bernutz,et al.  The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man. , 1983, Circulation.

[24]  A. M. Lefer,et al.  Protection of Ischemic Cat Myocardium By CGS‐13080, a Selective Potent Thromboxane A2 Synthesis Inhibitor , 1983, Journal of cardiovascular pharmacology.

[25]  L. Becker,et al.  Salvage of ischemic myocardium by prostacyclin during experimental myocardial infarction. , 1983, Journal of the American College of Cardiology.

[26]  F. Clerck,et al.  Platelet-mediated vascular contractions. Inhibition by flunarizine, a calcium-entry blocker. , 1983 .

[27]  A. M. Lefer,et al.  Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor. , 1983, British journal of clinical pharmacology.

[28]  H. Deckmyn,et al.  A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. , 1982, Thrombosis research.

[29]  P. Halushka,et al.  Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. , 1981, Thrombosis research.

[30]  J. Parratt,et al.  Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias , 1981, Nature.

[31]  M. Fishbein,et al.  Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. , 1981, American heart journal.

[32]  S. Epstein,et al.  Influence of sulfinpyrazone and naproxen on infarct size in the dog. , 1981, The American journal of cardiology.

[33]  R. Bonow,et al.  Lack of effect of aspirin on myocardial infarct size in the dog. , 1981, The American journal of cardiology.

[34]  A. M. Lefer,et al.  Role of Prostacyclin in the Preservation of Ischemic Myocardial Tissue in the Perfused Cat Heart , 1980, Circulation research.

[35]  E. Braunwald,et al.  Autoradiographic method for measuring the ischemic myocardium at risk: effects of verapamil on infarct size aftr experimental coronary artery occlusion. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Herman,et al.  Blood levels of 6-oxo-prostaglandin F1α during endotoxin-induced hypotension in rabbits , 1980 .

[37]  E. F. Smith,et al.  Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. , 1980, Canadian journal of physiology and pharmacology.

[38]  J. Ferrendelli,et al.  Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Vane,et al.  Imidazole: a selective inhibitor of thromboxane synthetase. , 1977, Prostaglandins.

[40]  A. M. Lefer,et al.  Influence of nonsteroidal anti-inflammatory agents on myocardial ischemia in the cat. , 1976, The Journal of pharmacology and experimental therapeutics.

[41]  R. Kloner,et al.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog. , 1974, The Journal of clinical investigation.

[42]  M. Hamberg,et al.  Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Goldfarb,et al.  Beneficial effects of prostaglandin F2α in experimental myocardial infarction , 1974 .

[44]  M. Noble,et al.  Total and Regional Coronary Blood Flow Measured by Radioactive Microspheres in Conscious and Anesthetized Dogs , 1969, Circulation research.